Glycogen synthase kinase 3β (GSK3β) phosphorylates substrates, including the microtubule-associated protein tau, at both primed and unprimed epitopes. GSK3β phosphorylation of tau negatively regulates tau-microtubule interactions, however the differential effects of phosphorylation at primed and unprimed epitopes on tau is unknown. To examine the phosphorylation of tau at primed and unprimed epitopes and how this impacts tau function, the R96A mutant of GSK3β was used, a mutation that prevents phosphorylation of substrates at primed sites. Both GSK3β and GSK3β-R96A efficiently phosphorylated tau in situ. However, expression of GSK3β-R96A resulted in significantly less phosphorylation of tau at primed sites compared to GSK3β.
INTRODUCTION
Tau is a family of microtubule-associated proteins that are expressed predominantly in neurons and are produced by alternative splicing of a single gene (1, 2) . Although tau likely plays a role in numerous neuronal processes, such as vesicle transport (3, 4) , microtubule-plasma membrane interactions (5, 6 ) and the intracellular localization of protein such as fyn (7, 8 ), 14-3-3 (9, 10) and protein phosphatase 2A (11, 12) , the best characterized function of tau is the binding and stabilization of microtubules (13) (14) (15) .
Tau is a phosphoprotein and in vitro, numerous studies have demonstrated that sitespecific phosphorylation of tau regulates its ability to bind and stabilize microtubules.
Increased phosphorylation of tau in situ tends to negatively regulate tau-microtubule interactions (16) (17) (18) (19) (20) , although the effects of site-specific tau phosphorylation on microtubule binding in the cell have not been as thoroughly studied, as they have been in vitro.
Numerous protein kinases phosphorylate tau in vitro, however in situ the list is much more abbreviated. Protein kinase A (21), microtubule affinity regulating kinases (22) , cyclin dependent protein kinase 5 1 4 factors such as β-catenin, CREB and cytoskeletal proteins such as MAP1B and tau regulate their function (31) . Although numerous GSK3β substrates have been identified, the consensus sites recognized by GSK3β are not straightforward. GSK3β can phosphorylate "unprimed" sites at Ser/Thr-Pro motifs. Examples of unprimed substrates are axin and adenomatous polyposis coli gene product (APC) (32) (33) (34) . In other cases the substrate must first be phosphorylated at a site that is 4 amino acids C-terminal to the target site, which "primes" the substrate for phosphorylation by GSK3β. This "primed" motif (S/T-X-X-X-S/T[P]) often occurs in proline-rich regions of the substrate (32, 35) . Glycogen synthase (36) , eukaryotic protein synthesis initiation factor 2B (eI2B) (37) and β-catenin (38) are all primed substrates. Indeed, it appears as if the majority of GSK3β substrates are actually primed (35) . Interestingly, although GSK3β phosphorylates tau at unprimed sites (39, 40) , prior phosphorylation by cdk5/p25 [p25] enhances the phosphorylation of tau at specific sites (e.g. Thr231) (41, 42) , indicating that tau may be both a primed and unprimed substrate of GSK3β.
GSK3β activity is regulated by its phosphorylation state. Phosphorylation of GSK3β on Tyr216 increases its activity (43) , and phosphorylation at Ser9 inhibits kinase activity (44, 45) , and both these events are regulated by growth factor signaling (31) . In response to insulin or insulin-like growth factor, Akt is activated and this kinase 5 47). Mutation of Arg96 to Ala significantly decreased the ability of GSK3β to phosphorylate primed substrates, but had no effect on its ability to phosphorylate unprimed sites (32) .
Although there is data to suggest that tau is both a primed and unprimed site of GSK3β in situ, this has not been clearly demonstrated. Further, how phosphorylation of tau by GSK3β on different sites modulates its association with microtubules has not been thoroughly explored. By using wild type GSK3β, and GSK3β with the R96A or S9A mutation we demonstrate that GSK3β phosphorylates tau at both primed sites (pThr231) and unprimed sites (pSer396/404). Disruption of the GSK3β phosphate binding pocket (R96A mutation) results in a significant decrease in tau phosphorylation at the primed site of Thr231 and an enhancement of phosphorylation at the unprimed site of Ser396/404. Further, GSK3β-R96A phosphorylates recombinant tau to a significantly greater extent than wild type or S9A-GSK3β, however if tau is first phosphorylated by cdk5/p25 then GSK3β-R96A is significantly less effective than wild
Immunoblotting -Cells were collected in lysis buffer (150 mM NaCl, 10 mM Tris-HCl, 1mM EGTA, 1 mM EDTA, 0.2 mM sodium vandate, 0.5% Nonidet P-40), containing 1 mM phenyl methyl sulfonyl fluoride, 0.1 µM okadaic acid, and a 10 µg/ml concentration each of aprotonin, leupeptin, and pepstatin. Lysates were sonicated on ice, centrifuged, and protein concentrations in the supernatants were determined using the bicinchoninic acid assay (Pierce). Equal amounts of protein from each sample were electrophoresed on 10% SDS-polyacrylamide gels, transferred to nitrocellulose, and probed with the indicated antibodies. The tau antibodies used in this study were Tau5/5A6 (Tau5 from Dr. L. Binder), which are phospho-independent tau antibodies (49-51), AT180 (Innogenetics), which recognizes tau when it is phosphorylated at Thr 231 and Ser 235 (52, 53) , and PHF1 (from Dr. P. Davies), which recognizes tau phosphorylated at Ser396/404 (54). The monoclonal GSK3β was purchased from Transduction Labs; the monoclonal cdk5 antibody was from Santa Cruz, the monoclonal β-tubulin antibody was from Sigma, the monoclonal β-actin antibody was from Chemicon and the monoclonal HA antibody was from Roche. After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Labs), the blots were developed using enhanced chemiluminescence (Amersham).
8 immunoprecipitated Cdk5/p25 with 40 µl kinase buffer containing 20 mM Tris, pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 250 µM ATP, and 0.2 µg/µl recombinant tau protein (Takara/Panvera, Madison, WI). For the negative control, the reaction was performed without ATP in the kinase buffer. The samples were incubated at 30°C for 30 min with shaking and then spun to pellet the cdk5/p25 immune complex. The supernatants containing the recombinant tau were collected and dialyzed to remove free ATP using Slide-A-Lyzer Mini Dialysis Units (Pierce). Following dialysis, protein concentrations were determined by using the bicinchoninic acid assay. The supernatants were immunoblotted for cdk5 to confirm that there was no cdk5 present. proteins were separated on 10% SDS-polyacrylamide gels. The gels were vacuumdried, exposed to a phosphoscreen overnight, and quantitated using a PhosphoImager (Molecular Dynamics, Sunnyvale, CA). The efficiency of HA immunoprecipitation was determined by immunoblotting for GSK3β.
Measurement of GSK3β activity
In indicated experiments, the activity of GSK3β was measured using a primed peptide substrate, phospho-glycogen synthase peptide-2 (Upstate Biotechnology) as previously described (55) glycerol, 10 mM benzamidine, 50 µg/ml leupeptin, 1.0 mM phenyl methyl sulfonyl fluoride and 0.5 µM okadaic acid]. Cells were then incubated in 300 µl (for a 60-mm plate) of extraction buffer containing 0.1% tritonX-100 for 10 min at 37°C. Cells were transferred into microcentrifuge tubes and centrifuged for 2 min at 16,000 g. The supernatant was removed and incubated in a boiling-water bath for 10 min, while the pellet was resuspended in 100 µl of 2x SDS stop buffer, without dithiothreitol or dye, and sonicated. Protein determinations were made and samples were diluted with 2x SDS stop buffer, boiled, electrophoresed on SDS/polyacrylamide gels and immunoblotted as described above.
Microtubule binding assay using cell lysates -The microtubule-binding assay was carried out as described previously with a few modifications (6) . Cells were collected and resuspended in 80 mM PIPES/KOH (pH 6.8) and 1 mM CaCl 2 , and protease and phosphatase inhibitors. Cell suspensions were briefly sonicated on ice and incubated on ice for 15 min. Samples were brought to 1.5 mM EGTA and centrifuged at 100, 000 X g for 1 hr at 4ºC. Equal amounts of protein lysate were used in each binding assay.
Supernatants were adjusted to 1 mM GTP and 10 μM taxol and incubated with taxolstabilized microtubules (30 µM) prepared from rat brain (56) The samples were incubated at 30°C for 1 hr with shaking and then spun to pellet the GSK3β immune complex. Phosphorylated or control tau (100 ng) was diluted in 80 mM PIPES/KOH (pH 6.8), 1.5 mM EGTA. The samples were adjusted to 1 mM GTP and 10 μM taxol and incubated with taxol-stabilized microtubules (20 µM) in a final volume of 30 µl for 10 min at 37 ºC. The mixtures were centrifuged through 100 μl of 30% (w/v) sucrose cushions in 80 mM PIPES/KOH containing 1 mM EGTA, 1 mM GTP and 10 μM taxol, at 100,000 X g for 30 min in an airfuge at room temperature. The supernatant and pellet were collected and processed as described above.
RESULTS

Wild type and R96A-GSK3β differentially phosphorylate tau -To determine if GSK3β
differentially phosphorylates tau when the phosphate-binding pocket of GSK3β is disrupted, cells were transfected with tau alone, or with tau and HA-GSK3β, HA-GSK3β-R96A or HA-GSK3β-S9A. Lysates were collected and immunoblotted with the phosphate-independent tau antibodies Tau5/5A6, AT180 which recognizes tau when both Thr231 and Ser235 are phosphorylated (a primed site), PHF-1 which recognizes tau when Ser396/404 are phosphorylated (unprimed sites), a GSK3β antibody or a β-actin antibody. In the absence of exogenous GSK3β tau migrated as a doublet that was not recognized by either AT180 or PHF-1 (Fig. 1) . Co-expression of either the wild type or mutant GSK3β resulted in a significant decrease in the mobility of tau, however in the presence of HA-GSK3β or HA-GSK3β-S9A tau migrated as a distinct doublet. In contrast, in the presence of HA-GSK3β-R96A, tau always presented as a "blurred" band(s); two distinct tau bands were never observed (also see Fig. 5B ). This differential migration of tau in the presence of HA-GSK3β-R96A compared with HA-GSK3β or HA-GSK3β-S9A is likely due to the differential phosphorylation of tau by HA-GSK3β-R96A.
Expression of either HA-GSK3β or HA-GSK3β-S9A with tau resulted in a robust increase in AT180 immunoreactivity, and to a lesser extent increased PHF-1 staining. In contrast to these findings, expression of HA-GSK3β-R96A resulted in large increase in PHF-1 immunoreactivity, and only a minimal increase in AT180 immunoreactivity (Fig.   1 ). In all cases wild type and mutant GSK3β were expressed at similar levels (Fig. 1) .
These results suggest that tau is both a primed and unprimed substrate of GSK3β.
R96A-GSK3β efficiently phosphorylates recombinant tau -The in vitro activity of the different GSK3β constructs toward primed and unprimed substrates was examined.
Cells were transfected with HA-GSK3β, HA-GSK3β-R96A or HA-GSK3β-S9A immunoprecipitated with the HA antibody and used in the in vitro kinase assays. All the GSK3β constructs efficiently phosphorylated recombinant tau, however HA-GSK3β-R96A phosphorylated recombinant tau approximately 4 fold more than HA-GSK3β or HA-GSK3β-S9A ( Fig. 2A) . In contrast, and as expected (32) , HA-GSK3β-R96A was extremely inefficient in phosphorylating a primed peptide, showing activity that was less than 20% of the activity of HA-GSK3β or HA-GSK3β-S9A (Fig. 2B) . To determine whether GSK3β phosphorylates primed tau in a manner similar to the primed peptide, tau was pre-phosphorylated with cdk5/p25 as described in the Experimental procedures section, prior to use in the in vitro kinase assay. After preparation of the primed or control tau (No ATP in the reaction), no cdk5 was present in the tau fractions as confirmed by immunoblotting for cdk5 (data not shown). Priming of recombinant tau prior to phosphorylation by the GSK3β constructs demonstrated that HA-GSK3β-R96A
was not as efficient as HA-GSK3β or HA-GSK3β-S9A in phosphorylating primed tau (Fig. 2C, left panel) . In contrast, HA-GSK3β-R96A phosphorylated the control, mock phosphorylated tau much more efficiently than HA-GSK3β or HA-GSK3β-S9A (Fig. 2C,   right panel) . These results clearly demonstrate that both in situ and in vitro tau is both a primed and unprimed substrate of GSK3β.
Tau phosphorylated at a primed site is only present in the soluble fraction -To determine whether there is a differential distribution of tau phosphorylated at primed (AT180) and unprimed (PHF-1) sites, cells were transfected with tau alone or tau with one of the GSK3β constructs, and the detergent-insoluble cytoskeleton was separated from the detergent-soluble fraction. These results (Fig. 3) clearly demonstrate that tau phosphorylated at primed sites (AT180) is only present in the soluble fractions, while tau phosphorylated at unprimed sites (PHF-1) is present in both the soluble and insoluble fractions.
Primed phosphorylation sites of tau regulate the intracellular localization of tau -
The next experiment was to determine how GSK3β-mediated phosphorylation of tau at primed and unprimed sites regulates the association of tau with the cytoskeleton. Cells were transfected with tau alone or with tau and one of the GSK3β constructs and the cells were fractionated and the distribution of tau between the soluble and insoluble fractions was determined (Fig. 4) . Co-expression of HA-GSK3β or HA-GSK3β-S9A with tau increased the amount of tau in the soluble fraction compared to what was observed in cells transfected with tau alone, indicating that GSK3β changed the binding affinity of tau for the cytoskeleton/microtubules (Fig. 4) . In contrast co-expression of HA-GSK3β-R96A with tau did not result in an obvious increase in soluble tau levels (Fig. 4) . These data suggest that phosphorylation of tau at primed sites may regulate tau's association with microtubules, while GSK3β-mediated phosphorylation at unprimed sites does not significantly impact tau-microtubule interactions.
Phosphorylation of tau at unprimed sites by GSK3β-R96A does not decrease microtubule binding -To further determine the functional significance of tau phosphorylation by GSK3β at primed and unprimed sites, a microtubule sedimentation assay was performed. High speed supernatants from cells transfected with tau alone or tau and HA-GSK3β, HA-GSK3β-R96A or HA-GSK3β-S9A were incubated with taxol stabilized microtubules and the amount of tau bound to the microtubules in the pellet and the amount of tau that remained unbound was measured. In the absence of GSK3β, all the tau was in the microtubule bound pellet. In contrast, when tau was coexpressed with HA-GSK3β or HA-GSK3β-S9A a significant amount of tau was observed in the unbound fraction and was recognized by AT180 (Fig. 5A) . Interesting, no PHF-1 immunoreactivity was observed in the unbound fractions. Further, co-expression of tau and HA-GSK3β-R96A did not result in an increase in unbound tau even though there was a significant increase in PHF-1 immunoreactivity in the bound fraction. Figure 5B shows that the expression of tau and GSK3β was equivalent in all conditions. These results indicate that phosphorylation of tau by GSK3β at primed sites is necessary to decrease the affinity of tau for microtubules, while phosphorylation at unprimed sites, such as PHF-1, does not significantly effect tau-microtubule interactions.
To further confirm that the phosphorylation of tau at primed sites plays an important role in regulating tau's interaction with microtubules, recombinant tau was phosphorylated with immunoprecipitated HA-GSK3β, HA-GSK3β-S9A or HA-GSK3β-R96A, or with immunoprecipitates from vector transfected cells. The phosphorylated recombinant tau was then used in a microtubule-binding assay and the amount of bound and free tau was determined. These results (Fig. 6 ) again demonstrate that phosphorylation of tau by HA-GSK3β or HA-GSK3β-S9A increased the amount of unbound tau compared to controls, while tau phosphorylation by HA-GSK3β-R96A did not increase the level of unbound tau.
DISCUSSION
The aim of this study was to gain insight into the site-specific tau phosphorylation by GSK3β and to determine how phosphorylation of specific epitopes on tau affects its function. Our results clearly demonstrate that GSK3β phosphorylates tau on both primed and unprimed sites, however it is the phosphorylation of tau at the primed epitopes that decreases tau-microtubule interactions.
It has been unequivocally demonstrated that GSK3β phosphorylates tau in situ, however most studies have focused the phosphorylation of unprimed sites such as PHF-1, Tau-1 and AT8 (25, 28, (57) (58) (59) , although in a transgenic mouse model that expressed both human tau and S9A-GSK3β an increase in AT180 immunoreactivity was noted (59) . In vitro it has been demonstrated that AT180 recognition of tau requires Thr231 to be phosphorylated, and GSK3β can phosphorylate tau on this site only when Ser235 is already phosphorylated (53) . Therefore, AT180 recognizes a primed GSK3β epitope. In situ we have shown that disruption of the priming phosphate-binding pocket in GSK3β by making the R96A mutation (32, 44) significantly impairs the ability of GSK3β to phosphorylate tau at the AT180 epitope, confirming the in vitro findings.
Further, priming of recombinant tau by "pre-phosphorylating" it with cdk5/p25 (41, 42) results in a decrease in tau phosphorylation by the GSK3β-R96A mutant compared to wild type GSK3β and GSK3β with the S9A mutation. Interestingly, wild GSK3β and GSK3β-S9A phosphorylated tau to similar extent however HA-GSK3β-R96A phosphorylated recombinant tau much more efficiently than both HA-GSK3β and HA-GSK3β-S9A. These data indicate that the enhancement of tau phosphorylation by the GSK3β-R96A mutant is not due to the inability of GSK3β-R96A to be inhibited by the pseudosubstrate of the phosphorylated N-terminal (32, 44) . In addition, tau phosphorylation at the non-primed PHF-1 epitope was much greater when cells were co-transfected with HA-GSK3β-R96A compared with HA-GSK3β or HA-GSK3β-S9A.
The reason for the enhancement in non-primed tau phosphorylation by the GSK-R96A mutant is unknown, but may be due to an increase in the accessibility of tau to the active site. However, the R96A mutation of GSK3β did not affect phosphorylation of axin or β-catenin (32).
GSK3β is a constitutively active kinase that is inactivated by Ser9 phosphorylation.
Engagement of signaling pathways that Akt results in GSK3β Ser9 phosphorylation and downregulation of GSK3β activity. In addition, other protein kinases such as protein kinase C and MAPKAP kinase 1 can phosphorylate Ser9 on GSK3β and downregulate its activity (31) . In almost all experiments in this study, GSK3β-S9A showed slightly, but not significantly, more activity than GSK3β. The likely reason for this observation is that all measures were done under basal conditions and not in the presence of signals that would activate Akt, and therefore the effects of the S9A mutation on GSK3β activity were not prominent.
There is good evidence that in situ GSK3β-mediated tau phosphorylation decreases tau's affinity for microtubules. For example, microtubule depolymerization in response to colchicine treatment was greater in cells transfected with tau and GSK3β compared to cells transfected with tau (57, 60) and cells co-transfected with tau and GSK3β exhibited a reduction in microtubule bundling compared to cells transfected with tau alone (26) .
Further, in mice transgenic for GSK3β-S9A and tau, increased tau phosphorylation occurred, as well a reduction in the axonopathy that was observed in the mice that just overexpressed human tau (59) . The reduction in the axonopathy in response to increased expression of GSK3β-S9A is likely due to the fact that the increase in tau phosphorylation resulted in a decrease in tau-microtubule interactions, which thus alleviated the inhibition in axonal transport due to tau overexpression (3, 59) . Although it is clear that tau is phosphorylated by GSK3β on numerous sites, the contribution of these different sites to the regulation of tau function in situ has not been thoroughly explored. In this study we show that although GSK3β-R96A efficiently phosphorylates tau in situ at non-primed sites, and this results in a decrease in the electrophoretic mobility of tau, this did not result in an increase in the amount of free, non-microtubule bound tau. This is in contrast to wild type GSK3β or GSK3β-S9A, which did cause an increase in the levels of unbound tau. Further, AT180 immunoreactivity was only found in the soluble or unbound fraction, indicating that phosphorylation within this epitope, and/or at other primed sites may play an important role in regulating tau's interaction with microtubules. In contrast, PHF-1 immunoreactivity was found exclusively in the bound fractions (Fig. 5A) , indicating that phosphorylation of tau at this epitope and/or at other unprimed GSK3β sites plays less of a role in regulating tau-microtubule interaction. The finding that GSK3β phosphorylation of primed sites on tau may play a more significant role in regulating tau's function than unprimed sites is quite intriguing given the fact that the majority of GSK3β substrates are primed (35) . Additionally, recent data has shown that β-catenin, which was previously believed to be an unprimed substrate of GSK3β, is actually primed by casein kinase Iα (61). Further, different substrates of GSK3β require different priming protein kinases, such as protein kinase A for CREB and casein kinase II for glycogen synthase (31) and of course casein kinase Iα for β-catenin (61). Therefore one can speculate that the most functionally relevant GSK3β-mediated tau phosphorylation events are at primed epitopes, and that perhaps protein kinase(s) like cdk5/p25 may play an essential role in regulating GSK3β-mediated tau phosphorylation (41, 42) . Indeed, GSK3β and cdk5/p35[p25] co-purify together with tau and microtubules, and were originally referred to as tau protein kinase I and II, respectively (62) . A dual kinase system for the regulation of tau phosphorylation by GSK3β would give a high degree of control for GSK3β substrate selectivity and provide for the needed regulation of tau function in the cell. Further studies are required to fully elucidate the role of GSK3β-mediated tau phosphorylation at both primed and unprimed sites and how these site-specific phosphorylation events affect tau function. 
